The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets
Background: Platelet transfusions are a cornerstone of modern medical care, used across various clinical contexts. Ensuring the compatibility of blood products, especially regarding ABO isoagglutinins, is critical to minimize adverse reactions. Pathogen reduction technologies have been widely adopte...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137925001087 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849243034117472256 |
|---|---|
| author | Mikayel Yeghiazaryan Yembur Ahmad Jessie Singer Vaanush Nazaryan Craig Fletcher Yamac Akgun |
| author_facet | Mikayel Yeghiazaryan Yembur Ahmad Jessie Singer Vaanush Nazaryan Craig Fletcher Yamac Akgun |
| author_sort | Mikayel Yeghiazaryan |
| collection | DOAJ |
| description | Background: Platelet transfusions are a cornerstone of modern medical care, used across various clinical contexts. Ensuring the compatibility of blood products, especially regarding ABO isoagglutinins, is critical to minimize adverse reactions. Pathogen reduction technologies have been widely adopted to enhance the safety of blood products, however, the impact of such treatments on ABO isoagglutinin titers in platelet products remains unclear. Methods: This study analyzed 60 apheresis platelet donations, including type O, A, and B donors, using the INTERCEPT® Blood System for pathogen reduction. Samples were collected both from donor whole blood at the time of apheresis (Retention) and from the final pathogen-reduced platelet product after it had passed through the compound adsorption device (Post-CAD). ABO isoagglutinin titers, including both IgM and IgG classes, were measured using solid-phase technology on the NEO Iris platform. Results: This study found a significant reduction in IgM isoagglutinin titers in Post-CAD samples, with 99 % of Retention titers being greater than or equal to their Post-CAD counterparts. IgG titers exhibited more variability, with 9 % of Post-CAD samples displaying higher titers than Retention samples. Statistical analysis confirmed differences between Retention and Post-CAD samples for both IgM and IgG titers, with p-values <0.05 in most comparisons. Conclusion: Pathogen reduction using the INTERCEPT® Blood System effectively reduces ABO isoagglutinin titers in apheresis platelets, potentially lowering the risk of hemolytic transfusion reactions. This reduction is beneficial for safer out-of-group platelet transfusions, especially in vulnerable populations such as pediatric patients. These findings support the continued use of pathogen-reduced platelets in transfusion medicine to enhance both safety and availability of blood products. |
| format | Article |
| id | doaj-art-a3ea18b5597b4d759d676bddc6fe418d |
| institution | Kabale University |
| issn | 2531-1379 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Hematology, Transfusion and Cell Therapy |
| spelling | doaj-art-a3ea18b5597b4d759d676bddc6fe418d2025-08-20T03:59:37ZengElsevierHematology, Transfusion and Cell Therapy2531-13792025-07-0147310384010.1016/j.htct.2025.103840The impact of pathogen reduction on ABO isoagglutinin titers in apheresis plateletsMikayel Yeghiazaryan0Yembur Ahmad1Jessie Singer2Vaanush Nazaryan3Craig Fletcher4Yamac Akgun5Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USADepartment of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA; Department of Pathology, Keck School of Medicine of USC, Los Angeles, California, USADepartment of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USADepartment of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USADepartment of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA; Department of Pathology, Keck School of Medicine of USC, Los Angeles, California, USADepartment of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA; Department of Pathology, Keck School of Medicine of USC, Los Angeles, California, USA; Corresponding author. Yamac Akgun, Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles, Los Angeles, CA, USA.Background: Platelet transfusions are a cornerstone of modern medical care, used across various clinical contexts. Ensuring the compatibility of blood products, especially regarding ABO isoagglutinins, is critical to minimize adverse reactions. Pathogen reduction technologies have been widely adopted to enhance the safety of blood products, however, the impact of such treatments on ABO isoagglutinin titers in platelet products remains unclear. Methods: This study analyzed 60 apheresis platelet donations, including type O, A, and B donors, using the INTERCEPT® Blood System for pathogen reduction. Samples were collected both from donor whole blood at the time of apheresis (Retention) and from the final pathogen-reduced platelet product after it had passed through the compound adsorption device (Post-CAD). ABO isoagglutinin titers, including both IgM and IgG classes, were measured using solid-phase technology on the NEO Iris platform. Results: This study found a significant reduction in IgM isoagglutinin titers in Post-CAD samples, with 99 % of Retention titers being greater than or equal to their Post-CAD counterparts. IgG titers exhibited more variability, with 9 % of Post-CAD samples displaying higher titers than Retention samples. Statistical analysis confirmed differences between Retention and Post-CAD samples for both IgM and IgG titers, with p-values <0.05 in most comparisons. Conclusion: Pathogen reduction using the INTERCEPT® Blood System effectively reduces ABO isoagglutinin titers in apheresis platelets, potentially lowering the risk of hemolytic transfusion reactions. This reduction is beneficial for safer out-of-group platelet transfusions, especially in vulnerable populations such as pediatric patients. These findings support the continued use of pathogen-reduced platelets in transfusion medicine to enhance both safety and availability of blood products.http://www.sciencedirect.com/science/article/pii/S2531137925001087Pathogen reductionApheresis plateletsIsoagglutinin titersSolid phase |
| spellingShingle | Mikayel Yeghiazaryan Yembur Ahmad Jessie Singer Vaanush Nazaryan Craig Fletcher Yamac Akgun The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets Hematology, Transfusion and Cell Therapy Pathogen reduction Apheresis platelets Isoagglutinin titers Solid phase |
| title | The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets |
| title_full | The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets |
| title_fullStr | The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets |
| title_full_unstemmed | The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets |
| title_short | The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets |
| title_sort | impact of pathogen reduction on abo isoagglutinin titers in apheresis platelets |
| topic | Pathogen reduction Apheresis platelets Isoagglutinin titers Solid phase |
| url | http://www.sciencedirect.com/science/article/pii/S2531137925001087 |
| work_keys_str_mv | AT mikayelyeghiazaryan theimpactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT yemburahmad theimpactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT jessiesinger theimpactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT vaanushnazaryan theimpactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT craigfletcher theimpactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT yamacakgun theimpactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT mikayelyeghiazaryan impactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT yemburahmad impactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT jessiesinger impactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT vaanushnazaryan impactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT craigfletcher impactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets AT yamacakgun impactofpathogenreductiononaboisoagglutinintitersinapheresisplatelets |